台湾人群广泛干预措施对肝细胞癌的长期效果
该研究基于台湾1979-2016年0-84岁人群的肝癌死亡与发病登记数据,采用贝叶斯泊松回归分解分析,评估乙肝疫苗接种、全民医保和抗病毒治疗对肝癌发病率和病死率下降的相对贡献。结果显示疫苗接种使30岁及以下人群发病率降低35.9%,抗病毒治疗使30-49岁和50-69岁人群发病率分别降低14.9%和15.4%,全民医保显著降低病死率。
要点
- 乙肝疫苗接种使30岁及以下人群肝癌发病率降低35.9%。
- 抗病毒治疗使30-49岁和50-69岁人群肝癌发病率分别降低14.9%和15.4%。
- 全民医保显著降低所有年龄组的肝癌病死率,进而降低死亡率。
核心结论
- 疫苗接种和抗病毒治疗对降低年轻和中年人群的肝癌发病率和死亡率有效。
- 全民医保改善了所有年龄组的肝癌病死率。
研究设计与样本
- 基于人群的登记研究,收集1979-2016年0-84岁人群肝癌死亡和发病数据。
- 按干预措施划分为四个时期:1984年乙肝疫苗接种前(Period 1)、1984年普遍接种后(Period 2)、1995年全民医保后(Period 3)、2003年病毒性肝炎治疗后(Period 4)。
- 采用贝叶斯泊松回归模型进行死亡率分解分析,估计各干预对年龄别发病率和病死率下降的贡献。
主要发现
- 儿童、年轻和中年组死亡率大幅下降,老年组仅轻微下降。
- 死亡率下降部分归因于发病率降低,部分归因于全民医保带来的病死率显著下降。
- 乙肝疫苗接种使30岁及以下人群发病率降低35.9%(95%CI 26.8%-44.4%)。
- 抗病毒治疗使30-49岁人群发病率降低14.9%(95%CI 11.8%-17.9%),50-69岁人群降低15.4%(95%CI 14.1%-16.6%)。
临床怎么用
- 支持普遍乙肝疫苗接种作为预防肝癌的关键公共卫生策略。
- 对30-69岁人群推广抗病毒治疗以降低肝癌发病率。
- 全民医保覆盖有助于降低肝癌病死率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Taiwan has launched a series of population-wide interventions to prevent hepatocellular carcinoma (HCC) related to hepatitis B and C virus infection since 1984. We took this opportunity to investigate the impact of each intervention on the incidence and case-fatality rate of HCC, and assessed their relative contributions to the overall reduction in mortality during this period. METHODS: Population-based registry data on HCC mortality and incidence from individuals aged 0 to 84 years between 1979 and 2016 were collected before (Period 1) and after universal hepatitis B vaccination from 1984 (Period 2), universal health care from 1995 (Period 3), and viral hepatitis therapy from 2003 (Period 4). A Bayesian Poisson regression model was used for mortality decomposition analysis to estimate the respective contributions of these interventions to the reduction in age-specific incidence and case-fatality rates. RESULTS: Mortality declined substantially in children, young- and middle-aged groups, but only slightly decreased in the elderly group. The declining trends in mortality were in part explained by incidence reduction and in part by a remarkable decline in case-fatality rate attributed to universal health care. Hepatitis B vaccination led to a 35.9% (26.8% to 44.4%) reduction in incidence for individuals aged 30 years or below, whereas antiviral therapy reduced the incidence of HCC by 14.9% (11.8% to 17.9%) and 15.4% (14.1% to 16.6%) for individuals aged 30-49 years and 50-69 years, respectively. CONCLUSIONS: Vaccination and antiviral therapy were effective in reducing HCC incidence and mortality for the young and middle-aged groups, while the case-fatality rate was improved by universal health care for all age groups. LAY SUMMARY: Since 1984, a series of population-wide interventions have been launched in Taiwan to prevent viral hepatitis-related hepatocellular carcinoma, including a universal hepatitis B vaccination program (from 1984), universal health care (from 1995), and a national viral hepatitis therapy program (from 2004). Vaccination and antiviral therapy were effective in reducing HCC incidence and mortality for the young and middle-aged groups, while the case-fatality rate was improved by universal health care for all age groups.
引用
- Liao SH, Chen CL, Hsu CY, et al. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J Hepatol. 2021. PMID: 33689789. doi:10.1016/j.jhep.2021.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。